Abida Parveen

Dr. Abida Parveen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2025 in Medicine
Verified
Journal Article
Open access
MHMuhammad Bari Hassan
Muhammad Bari Hassan
SSSadia Siddique
Sadia Siddique
SMSandeep Kumar Maheshwari
Sandeep Kumar Maheshwari
FNFnu Neelam
Fnu Neelam
FNFnu Neha
Fnu Neha
APAbida Parveen
Abida Parveen
Background: Chronic kidney disease (CKD) is a major public health concern due to its association with increased cardiovascular risk. Patients with CKD, especially those with moderate to severe renal dysfunction, face a heightened risk of cardiovascular events and mortality. This systematic review evaluates the relationship between CKD and cardiovascular risk, focusing on the pathophysiology, risk factors, and clinical outcomes related to cardiovascular disease (CVD) in CKD populations. Methods: A comprehensive search of electronic databases was conducted for studies investigating CKD and cardiovascular risk. Seven studies, including cross-sectional, and cohort designs, were included in this review. These studies involved a total of 104,576 participants, with diverse stages of CKD and varying cardiovascular risk profiles. Data on renal dysfunction stages, cardiovascular risk factors, and mortality outcomes were extracted and analyzed. Results: The studies consistently demonstrated that CKD is associated with an increased risk of cardiovascular events, including coronary heart disease and stroke, compared to individuals without CKD. Even early stages of CKD were linked to a higher likelihood of CVD. Participants with CKD exhibited a greater burden of traditional cardiovascular risk factors, including hypertension, diabetes, dyslipidemia, and obesity. The overall mortality rate from cardiovascular causes was also higher in CKD patients, with some studies reporting a two-fold or greater increase in risk. Conclusion: CKD is strongly linked to an increased cardiovascular risk, with higher stages of renal dysfunction associated with a more significant risk of cardiovascular morbidity and mortality. This review emphasizes the need for early detection and comprehensive management of cardiovascular risk factors in CKD patients. Future research should focus on identifying novel biomarkers and evaluating the long-term efficacy of emerging therapies in reducing cardiovascular risk in CKD populations.

5 July 2025 in Clinical Cardiology
Verified
Journal Article
Open access
AAAbdul Nadeem Akhter
Abdul Nadeem Akhter
FAFnu Aisha
Fnu Aisha
AMAimen Binte Moazzam
Aimen Binte Moazzam
SKSardar Humayun Babar Khan
Sardar Humayun Babar Khan
Jahanzeb MalikJahanzeb Malik
Jahanzeb Malik
APAbida Parveen
Abida Parveen
Background: Epicardial fat thickness (EFT) is a visceral fat depot with pro‐inflammatory properties, located adjacent to coronary vessels, and has been proposed as a marker of coronary artery disease (CAD). This study aimed to evaluate the association between EFT and the presence and severity of CAD in patients with type 2 diabetes mellitus.Methods: This retrospective study was conducted at the Abbas Institute of Medical Sciences (AIMS) between January 2020 and March 2025 (Study ID: AIMS/25/007). A total of 2340 diabetic patients (mean age: 58.3 ± 9.6 years) were included. EFT was measured using transthoracic echocardiography, and CAD presence and severity were assessed via coronary angiography. Logistic regression analysis was used to evaluate associations, with results expressed as odds ratios (OR) with 95% confidence intervals (CI).Results: Elevated EFT (≥ 5 mm) was observed in 1281 patients (54.7%). CAD was present in 1121 individuals (47.9%), with significantly higher rates in those with elevated EFT (65.7% vs. 26.3%, p < 0.001). EFT ≥ 5 mm was associated with a 5.38‐fold increased odds of CAD (95% CI: 4.59–6.30, p < 0.001). Moreover, patients with elevated EFT had a significantly higher prevalence of multi‐vessel CAD, indicating a correlation between EFT and disease severity.Conclusions: In diabetic patients, elevated EFT is significantly associated with both the presence and severity of CAD. EFT measurement via echocardiography may serve as a simple, noninvasive tool for cardiovascular risk stratification and early intervention planning.

28 November 2025 in Medicine
Verified
Journal Article
Open access
HBHamza Bashir
Hamza Bashir
MAMuhammad Waqas Afzal
Muhammad Waqas Afzal
AMAsad Mehmood
Asad Mehmood
MAMaham Afzal
Maham Afzal
MHMuhammad Wasi Hassan
Muhammad Wasi Hassan
APAbida Parveen
Abida Parveen
Prostate cancer is a leading malignancy worldwide, and while radical prostatectomy is an effective treatment for localized disease, a significant proportion of patients experience biochemical recurrence. Prostate-specific antigen (PSA) remains the primary biomarker for recurrence detection, but its limitations in specificity necessitate improved surveillance tools. Liquid biopsy techniques, particularly exosomal microRNAs (miRNAs) and circulating tumor DNA (ctDNA), have emerged as promising noninvasive biomarkers for early recurrence detection. However, their comparative diagnostic accuracy remains unclear. This narrative review explores the diagnostic potential of exosomal miRNAs and ctDNA for early recurrence detection following radical prostatectomy. It examines their biological characteristics, detection methodologies, comparative diagnostic performance, and clinical challenges. Both exosomal miRNAs and ctDNA hold significant potential for the early detection of prostate cancer recurrence post-radical prostatectomy. However, the lack of standardized protocols and the variability in current studies limit definitive conclusions about their relative accuracy. Future large-scale, prospective studies are necessary to validate their clinical utility and establish guidelines for their integration into routine surveillance. A multi-biomarker approach combining exosomal miRNAs, ctDNA, and PSA may provide the most effective strategy for personalized prostate cancer monitoring.

31 July 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
ASAyesha Siddiqui
Ayesha Siddiqui
ABAruna Bai
Aruna Bai
HKHaresh Kumar
Haresh Kumar
YMYash Roop Mandhwani
Yash Roop Mandhwani
ABAnjali Bai
Anjali Bai
APAbida Parveen
Abida Parveen
Chronic urticaria (CU), especially chronic spontaneous urticaria (CSU), is a long-term inflammatory skin condition marked by wheals and/or angioedema lasting over six weeks. Emerging evidence suggests a link between vitamin D deficiency and immune dysregulation associated with CU. Given vitamin D’s immunomodulatory and anti-inflammatory effects, this review explores the therapeutic potential of vitamin D supplementation in CU management. A systematic review was conducted in accordance with PRISMA guidelines Electronic databases (PubMed, Scopus, Web of Science, and Google Scholar) were searched using relevant keywords. Studies included were randomized controlled trials (RCTs), case–control, and observational studies assessing serum vitamin D levels or supplementation in patients with CU. Data extraction and bias assessment were independently conducted using standardized tools: the Cochrane Risk of Bias Tool and the Newcastle–Ottawa Scale. Eleven studies involving 1,491 participants were included. Most studies demonstrated significantly lower serum 25(OH)D levels in patients with CU compared to healthy controls. Vitamin D supplementation, particularly in individuals with a deficiency, was associated with reductions in urticaria activity scores, symptom severity, and improved quality of life. High-dose regimens (e.g., 4,000 IU/day or 60,000 IU/week) appeared more effective. However, results varied due to heterogeneity in study design, dosage, and patient characteristics. Vitamin D supplementation may serve as a safe, accessible adjunct to standard CU treatment, particularly for those with confirmed deficiency. While evidence suggests potential benefits, further high-quality RCTs are needed to establish causality, optimal dosing, and long-term efficacy.

3 July 2025 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PDF file
MMMohammad Hamza Bin Abdul Maik
Mohammad Hamza Bin Abdul Maik
MIMuhammad Ibtisam
Muhammad Ibtisam
SSSarah Sheikh
Sarah Sheikh
MMMuhammad Awais Bin Abdul Malik
Muhammad Awais Bin Abdul Malik
AIAyesha Ihsan
Ayesha Ihsan
APAbida Parveen
Abida Parveen
Background Atherosclerosis, a major cause of cardiovascular morbidity and mortality, involves lipid accumulation, endothelial dysfunction, inflammation, and oxidative stress. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus (T2DM), have demonstrated cardiovascular benefits beyond glycemic control. Emerging evidence suggests their potential role in slowing atherosclerosis progression and enhancing plaque stability. Methods A systematic review of PubMed, Scopus, Embase, and Cochrane Library databases was conducted to identify preclinical and clinical studies on SGLT2 inhibitors and atherosclerosis. Studies published in English up to December 2024 were screened using predefined criteria. Data on mechanisms, lipid metabolism, endothelial function, vascular inflammation, and plaque stability were extracted, and study quality was assessed. Results A total of 16 animal and 4 human studies were included. SGLT2 inhibitors (empagliflozin, dapagliflozin, and canagliflozin) improved glycemic control, lipid metabolism, and atheroma reduction while enhancing plaque stability. They modestly reduced triglycerides and LDL-C while increasing HDL-C. SGLT2 inhibitors also decreased vascular inflammation and enhanced plaque stability by increasing fibrous cap thickness. Cardiovascular outcome trials demonstrated reductions in major adverse cardiovascular events (MACE) and heart failure hospitalizations, indirectly supporting their atheroprotective role. Conclusion SGLT2 inhibitors offer a multifaceted approach to atherosclerosis management by improving lipid metabolism, endothelial function, vascular inflammation, and plaque stability. While evidence is promising, further research is needed to confirm direct anti-atherosclerotic effects, optimize their role in cardiovascular care

17 October 2025 in Medicine
Verified
Journal Article
Open access
SFSaman Firdous
Saman Firdous
HAHamza Amjad
Hamza Amjad
MCMuhammad Umair Choudhary
Muhammad Umair Choudhary
MAMuhammad Waqas Afzal
Muhammad Waqas Afzal
RTRana Hamza Tayyab
Rana Hamza Tayyab
APAbida Parveen
Abida Parveen
Background: Psoriatic arthritis (PsA) is a chronic inflammatory condition characterized by joint involvement, enthesitis, dactylitis, and skin psoriasis. The pathophysiology of PsA is complex, driven by dysregulated immune responses, making targeted therapies essential for managing symptoms. Despite the success of biologic disease-modifying anti-rheumatic drugs (bDMARDs) like tumor necrosis factor (TNF) inhibitors, many patients experience suboptimal responses or adverse effects, necessitating the development of new therapies. Emerging biologics targeting interleukin (IL)-17, IL-23, and Janus kinase (JAK) pathways offer promising alternatives. This review aims to evaluate the efficacy and safety of emerging biologics for PsA. Methods: A systematic review of studies published from 2000 to December 2024 was conducted. Randomized controlled trials (RCTs), cohort studies, and clinical trials were included to assess the efficacy, safety, and adverse effects of bDMARDs and targeted synthetic DMARDs (tsDMARDs) for PsA treatment. Studies focusing on other aspects of psoriasis or nonpharmacological treatments were excluded. Key data extracted included study design, treatment type, efficacy measures (e.g., ACR response), and safety outcomes. Results: A total of 20 studies involving 77,124 participants were reviewed. Biologic DMARDs such as TNF inhibitors, IL-17 inhibitors (e.g., secukinumab, ixekizumab), and IL-23 inhibitors (e.g., guselkumab) showed high efficacy in managing both joint and skin symptoms. Emerging therapies like bimekizumab (targeting IL-17A and IL-17F) demonstrated enhanced efficacy compared to traditional biologics. Conventional DMARDs, such as cyclosporine and leflunomide, were less effective but still showed moderate benefits. Safety profiles were generally favorable, with biologics showing fewer adverse effects than conventional therapies. Conclusion: Emerging biologics have significantly advanced the management of PsA, offering greater efficacy and safety compared to conventional DMARDs. IL-17 and IL-23 inhibitors, along with newer agents like bimekizumab, present promising treatment options for patients with inadequate responses to TNF inhibitors. Personalized treatment strategies, based on disease phenotype and individual patient needs, are essential for optimizing outcomes in PsA management. Further research into long-term efficacy and safety is required to refine treatment protocols and improve patient outcomes.